Literature DB >> 23283410

Circulating sex steroids and prostate cancer: introducing the time-dependency theory.

Andrea Salonia1, Firas Abdollah, Umberto Capitanio, Nazareno Suardi, Andrea Gallina, Giulia Castagna, Maria Chiara Clementi, Alberto Briganti, Patrizio Rigatti, Francesco Montorsi.   

Abstract

PURPOSE: We sought whether serum total testosterone (tT), estradiol (E2), tT/E2 ratio, and sex hormone-binding globulin (SHBG) significantly fluctuate throughout time in men with prostate cancer (PCa).
METHODS: Circulating hormones were measured in a cohort of 631 candidates for radical prostatectomy. Hormone levels were analyzed according to either patient age, stratified into quartiles, or body mass index (BMI). Linear regression analyses tested the association between sex steroids and continuously coded patient age and BMI values.
RESULTS: No significant differences were found among age quartiles regarding serum tT levels and tT/E2 ratio. Conversely, E2 and SHBG levels significantly increased throughout time (all, p ≤ 0.001). Total T did not linearly change according to continuously coded patient age; in contrast, E2 and SHBG linearly increased (all, p ≤ 0.001), whereas tT/E2 decreased (p = 0.016) with aging. Rate of hypogonadism significantly increased with aging (p = 0.04). Total T, T/E2 ratio, and SHBG linearly decreased along with BMI increases (all p ≤ 0.02), whereas serum E2 did not significantly change. Rate of hypogonadism significantly increased with BMI increases (p < 0.001).
CONCLUSIONS: In contrast with longitudinal studies in the general male population, these data indirectly suggest that serum tT levels could be stable over time in PCa patients. This finding led to formulation of a "time-dependency theory", which postulates that the endocrine biology of prostate tissue is dependent on the exposure time at a given concentration of sex steroid, which, in turn, fluctuates throughout the lifespan of the individual.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283410     DOI: 10.1007/s00345-012-1009-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

1.  Identification of late-onset hypogonadism in middle-aged and elderly men.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

2.  Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.

Authors:  Takashi Imamoto; Hiroyoshi Suzuki; Satoshi Fukasawa; Masaki Shimbo; Masahiko Inahara; Akira Komiya; Takeshi Ueda; Taizo Shiraishi; Tomohiko Ichikawa
Journal:  Eur Urol       Date:  2004-12-29       Impact factor: 20.096

3.  Prostate cancer does not influence androgen levels: a radical prostatectomy cohort study.

Authors:  Cosimo De Nunzio; Alfonso Carluccini; Antonio Cicione; Stefano Squillacciotti; Alberto Trucchi; Andrea Cantiani; Costantino Leonardo; Andrea Tubaro
Journal:  Urol Int       Date:  2011-01-21       Impact factor: 2.089

4.  Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.

Authors:  K Suzuki; T Nishiyama; N Hara; K Yamana; K Takahashi; F Labrie
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-03-27       Impact factor: 5.554

Review 5.  Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.

Authors:  Tim M van der Sluis; André N Vis; R Jeroen A van Moorselaar; Hong N Bui; Marinus A Blankenstein; Eric J H Meuleman; Annemieke C Heijboer
Journal:  BJU Int       Date:  2011-10-12       Impact factor: 5.588

6.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.

Authors:  William Rosner; Richard J Auchus; Ricardo Azziz; Patrick M Sluss; Hershel Raff
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

7.  Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy.

Authors:  Stuart J Ellem; Hong Wang; Matti Poutanen; Gail P Risbridger
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

8.  Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?

Authors:  Jakob E Lackner; Isabel Maerk; Anke Koller; Christian Bieglmayer; Michael Marberger; Christian Kratzik; Georg Schatzl
Journal:  Urology       Date:  2008-04-14       Impact factor: 2.649

9.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel; Stephanie T Page; Daniel W Lin; Ladan Fazli; Ilsa M Coleman; Lawrence D True; Beatrice Knudsen; David L Hess; Colleen C Nelson; Alvin M Matsumoto; William J Bremner; Martin E Gleave; Peter S Nelson
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

10.  Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.

Authors:  Andrea Salonia; Firas Abdollah; Umberto Capitanio; Nazareno Suardi; Alberto Briganti; Andrea Gallina; Renzo Colombo; Matteo Ferrari; Giulia Castagna; Patrizio Rigatti; Francesco Montorsi
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

View more
  3 in total

1.  Somatic mutational profiles and germline polygenic risk scores in human cancer.

Authors:  Yuxi Liu; Alexander Gusev; Yujing J Heng; Ludmil B Alexandrov; Peter Kraft
Journal:  Genome Med       Date:  2022-02-11       Impact factor: 15.266

Review 2.  Testosterone Replacement Therapy and Prostate Cancer Incidence.

Authors:  Michael Louis Eisenberg
Journal:  World J Mens Health       Date:  2015-12-23       Impact factor: 5.400

3.  Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.

Authors:  Carolina Bonilla; Sarah J Lewis; Richard M Martin; Jenny L Donovan; Freddie C Hamdy; David E Neal; Rosalind Eeles; Doug Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch; Kenneth Muir; Graham G Giles; Fredrik Wiklund; Henrik Gronberg; Christopher A Haiman; Johanna Schleutker; Børge G Nordestgaard; Ruth C Travis; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; William J Blot; Stephen Thibodeau; Christiane Maier; Adam S Kibel; Cezary Cybulski; Lisa Cannon-Albright; Hermann Brenner; Jong Park; Radka Kaneva; Jyotsna Batra; Manuel R Teixeira; Hardev Pandha; Mark Lathrop; George Davey Smith
Journal:  BMC Med       Date:  2016-04-04       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.